Immunic, Inc. Common Stock

IMUX

Immunic, Inc. (IMUX) is a clinical-stage biopharmaceutical company focused on developing oral therapies for autoimmune and inflammatory diseases. The company's pipeline includes immune-modulating treatments aimed at conditions such as multiple sclerosis, ulcerative colitis, and psoriasis. Immunic's approach leverages innovative small molecule compounds designed to target specific pathways involved in immune system regulation.

$0.69 +0.00 (0.13%)
🚫 Immunic, Inc. Common Stock does not pay dividends

Company News

Celiac Disease Market Report 2025-2035: Drivers, Challenges, Opportunities, Industry Trends and Case Studies
GlobeNewswire Inc. • Researchandmarkets.Com • December 30, 2025

The global celiac disease market is experiencing significant growth driven by rising awareness of gluten-related disorders, improved diagnostic technologies, and expanding gluten-free product offerings. Key drivers include increased prevalence, advancements in diagnostics, and emerging pharmacological therapies. However, challenges such as high c...

Immunic And 2 Other Stocks Under $2 Insiders Are Buying
Benzinga • Avi Kapoor • February 29, 2024

The Dow Jones index closed lower by over 20 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable inside...

Why Startek Shares Are Trading Higher By 29%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga • Lisa Levin • October 10, 2023

Gainers SuperCom Ltd. (NASDAQ: SPCB) shares jumped 89% to $0.6805, after falling 13% on Monday. SMX (Security Matters) Public Limited Company (NASDAQ: SMX) shares climbed 87.1% to $3.18 after the company announced it secured a majority stake in True Gold Consortium. PowerFleet, Inc. (NASDAQ: PWFL) gained 42% to $2.80. Powerfleet and MiX Telemati...

Why Immunic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Benzinga • Lisa Levin • October 10, 2023

Gainers SuperCom Ltd. (NASDAQ: SPCB) shares rose 78.4% to $0.6425 in pre-market trading, after falling 13% on Monday. Immunic, Inc. (NASDAQ: IMUX) shares gained 13.2% to $1.80 in pre-market trading after the company disclosed positive interim data from Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis. Tempest Ther...

Immunic's (IMUX) Ulcerative Colitis Study Shows Positive Data
Zacks Investment Research • Zacks Equity Research • April 6, 2023

Immunic (IMUX) reports positive results from the maintenance phase of the phase II study evaluating its lead candidate, vidofludimus calcium, to treat patients with ulcerative colitis.

Related Companies